Inhibikase Therapeutics Inc Inc. (IKT) Price Performance: A Fundamental Analysis Perspective

Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded an increase of 56.69%. However, over the last six months, the performance has been weaker by 112.29%. The price of IKT decreased -6.40% over the last 30 days. And in the last five days, it has surged by 42.14%.

Inhibikase Therapeutics Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $4.35 on 06/02/23, while the lowest price for the same period was registered at $0.79 on 10/10/23.

52-week price history of IKT Stock

Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Inhibikase Therapeutics Inc’s current trading price is -54.27% away from its 52-week high, while its distance from the 52-week low is 151.90%. The stock’s price range during this period has varied between$0.79 and $4.35. The Inhibikase Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.56 million for the day, a figure considerably higher than their average daily volume of 58950.0 over last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Inhibikase Therapeutics Inc (IKT) has experienced a quarterly decline of -21.65% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 12.90M and boasts a workforce of 8 employees.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.0151, with a change in price of +0.7200. Similarly, Inhibikase Therapeutics Inc recorded 118,829 in trading volume during the last 100 days, posting a change of +56.69%.

IKT’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for IKT stands at 0.06. Similarly, the long-term debt-to-equity ratio is also 0.01.

IKT Stock Stochastic Average

As of today, Inhibikase Therapeutics Inc’s raw stochastic average for the last 50 days stands at 61.24%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 77.45%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 42.00% and 24.85%, respectively.

Most Popular